Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo

Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo

Background: Well-differentiated gastroenteropancreatic neuroendocrine neoplasms are rare tumors with a slow proliferation. They are virtually resistant to many DNA-damaging therapeutic approaches, such as chemo- and external beam therapy, which might be overcome by DNA damage inhibition induced by p...

Full description

Bibliographic Details
Main Authors: Franziska Briest, Eva J. Koziolek, Jakob Albrecht, Fränze Schmidt, Monique R. Bernsen, Joost Haeck, Anja A. Kühl, Dagmar Sedding, Teresa Hartung, Samantha Exner, Martina Welzel, Christian Fischer, Carsten Grötzinger, Winfried Brenner, Richard P. Baum, Patricia Grabowski
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Bortezomib
Neuroendocrine tumors
Peptide receptor radionuclide therapy (PRRT)
DNA repair
Combination therapy
Proteasome inhibition
Online Access:http://www.sciencedirect.com/science/article/pii/S147655862030172X

Internet

http://www.sciencedirect.com/science/article/pii/S147655862030172X

Similar Items